Developer docs
API playgroundTry for free, no card

Search company profiles

Decheng Capital

Full company profile

uuid00008uf

Namestring
Decheng Capital
Legal namestring
Decheng Capital LLC
Websiteurl
decheng.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Decheng Capital is a venture capital firm founded in 2012 that invests exclusively in life sciences companies, with assets under management of $2.5 billion or more. The firm is headquartered in Menlo Park, California, with additional offices in Shanghai and New York, providing a tri-continental footprint that supports cross-border deal flow between US and Asia-Pacific biotech ecosystems. Its portfolio spans 80 or more companies across therapeutics, diagnostics, and related life-sciences adjacencies, with the firm maintaining board or board-equivalent roles at more than 50 portfolio companies.

The firm's investment activity is concentrated in private and late-stage private financings, including PIPE transactions, Series A through C rounds, and selective co-leadership of larger syndicates. Recent transactions include a $100M PIPE for Remix Therapeutics (June 2026), a $150M co-led Series B for Syneron Bio (March 2026), and a Series A+ for Vivacta Biotechnology (April 2026). The firm has realized several large exits, notably the sale of portfolio company Alpine Immune Sciences to Vertex Pharmaceuticals for $4.9B in April 2024 and the sale of Prometheus Biosciences to Merck for $10.8B in April 2023, and has supported public-market transitions including the January 2026 IPO of portfolio company Aardvark Therapeutics.

Decheng's revenue model follows the standard venture capital structure of management fees on committed or invested capital plus carried interest on realized gains. The team comprises approximately 13 investment professionals, including recent senior hires Joan Chen (Vice President, July 2025) and Michael Notaras (Vice President, July 2023), suggesting deliberate capacity buildout at the senior investment level. Customer relationships are bilateral: portfolio companies as investees and limited partners as capital providers, with portfolio diversification across 80+ companies reducing single-asset concentration risk.

Short descriptiontext

Decheng Capital is a life-sciences-focused venture capital firm founded in 2012 with $2.5B+ AUM, based in Menlo Park with offices in Shanghai and New York, investing across 80+ therapeutic and diagnostic portfolio companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech private equity, healthcare growth equity, venture capital management, biopharma early stage investing
Industry1 code
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing
NAICS code1 code
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
SIC code1 code
  • Finance Services6199
Product category
Life Sciences Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Fund Management
TypeManaged Services
Description

As a venture capital/private equity firm managing over $2.5 billion in capital, Decheng generates revenue through management fees charged on assets under management and carried interest/performance fees on successful exits from portfolio companies. Returns are driven by equity ownership stakes in early-stage life science and growth-stage healthcare companies that may exit via IPO (NASDAQ, HKSE, SHA), strategic M&A (e.g., Merck, Vertex, Eli Lilly, Roche, Illumina), or other liquidity events.

decheng.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Decheng Capital is a venture capital and private equity firm that provides equity capital and active strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with strong market presence. The firm manages over $2.5 billion in assets and invests across biopharma, diagnostics and tools, medical devices, and services, with offices in Silicon Valley, Shanghai, and New York enabling cross-border US-China deal flow. Revenue is generated through management fees on AUM and carried interest/performance fees on successful portfolio exits via IPO, M&A, or other liquidity events.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Led a $100 million oversubscribed private placement financing for Remix Therapeutics in connection with its merger with Passage Bio (announced 2026-06-24).
+4 more records
Product overview1 text field

Decheng Capital operates as a single global life sciences investment platform rather than a multi-product suite. Founded in 2012 by Dr. Min Cui, the firm manages over $2.5 billion in assets and provides capital and strategic support to portfolio companies spanning four categories: Biopharma (e.g., Aardvark Therapeutics, CG Oncology, Mammoth Biosciences, Mirvie, Shape Therapeutics, Syneron Bio, Vivacta Biotechnology), Diagnostics and Tools (e.g., Adaptive Biotechnologies, Encodia, LevitasBio, Watchmaker Genomics, AccuraGen), Medical Device (e.g., Nalu Medical, Polares Medical, Centricity Vision, SINO Medical), and Services (e.g., USCI Medical Laboratory). The firm's offering is unified — a life sciences venture capital platform — and is delivered through offices in Silicon Valley (Menlo Park), Shanghai, and New York. Portfolio companies include notable IPOs and exits such as Adaptive Biotechnologies (NASDAQ: ADPT), 3SBio (HKSE: 1530), AK Medical (HKSE: 1789), Invitae (NASDAQ: NVTA), GRAIL (acquired by Illumina), Cue Health (NASDAQ: HLTH), Arcus Biosciences (NASDAQ: RCUS), Terns Pharmaceuticals (NASDAQ: TERN), CG Oncology (NASDAQ: CGON), and others.

Product and service3 records
1Early-Stage Life Sciences Venture Capital Investment
CategoryLife Sciences Venture Capital
Description

Equity capital and active strategic support for early-stage life science companies with revolutionary technologies, including board representation and operational involvement. Targets biopharma, diagnostics, medical devices, and tools/services platforms.

2Growth-Stage Healthcare Growth Equity Investment
CategoryLife Sciences Venture Capital
Description

Growth-stage capital and strategic support to healthcare companies with strong market presence, helping them scale commercialization, expand geographically (especially into China and the US), advance clinical pipelines, and execute cross-border strategies.

3Cross-Border US-China Life Sciences Investment Platform
CategoryLife Sciences Venture Capital
Description

Integrated investment platform spanning US and China life sciences markets, providing portfolio companies with cross-border strategic support including US clinical development expertise, FDA and NMPA regulatory navigation, China clinical trial site and manufacturing partner access, and global partnership facilitation.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global healthcare-dedicated investment firm managing ~$17B across private equity, royalty, and public market strategies. Highly comparable to Decheng in life sciences focus and cross-border US-Asia investment activity, with a similar breadth of biopharma, medtech, and diagnostics exposure.

TypeDirect peer
Description

Life sciences-focused venture capital firm based in San Francisco where multiple Decheng senior team members previously worked (Min Cui, Victor Tong, Dayton Misfeldt, Nick Pliam). Closely comparable investment thesis in biopharma and tools, with similar stage and check-size orientation.

TypeDirect peer
Description

US-based healthcare-dedicated venture and growth firm investing across biopharma, medical devices, and healthcare services. Comparable in life sciences focus, stage breadth (seed through growth), and portfolio size; Peter Colabuono joined Decheng from Frazier.

TypeDirect peer
Description

Premier US life sciences venture firm investing across early-stage biotech, genomics, and platform technologies with deep scientific advisor networks. Comparable in modality focus (gene editing, cell therapy, diagnostics) and ability to lead large private financings.

TypeDirect peer
Description

Boston-based early-stage life sciences venture firm building biotech companies from inception. Comparable in investing across novel modalities (RNA, cell therapy, gene therapy) and stage focus, with comparable check sizes and board-driven model.

TypeDirect peer
Description

China-based venture firm with significant healthcare and biotech investment activity, frequently co-investing with Decheng (Syneron Bio Series B, others). Comparable in cross-border US-China life sciences investing and biotech platform thesis.

TypeDirect peer
Description

China-focused investment firm with active healthcare/biotech practice; co-led Vivacta Biotechnology Series A alongside Decheng. Directly comparable as a cross-border life sciences investor with similar modality and stage preferences.

TypeDirect peer
Description

China-based venture firm investing in technology and healthcare; Joan Chen joined Decheng from 5Y Capital. Comparable in cross-border China-US life sciences investing and stage preferences for early through growth healthcare companies.

TypeDirect peer
Description

US-based biotech-focused investment firm investing across early-stage and public equities in oncology and other life sciences. Comparable in dedicated life sciences focus, ability to lead and co-lead large financings, and portfolio depth.

TypeBroad incumbent
Description

Larger life sciences innovation firm that originates and builds biotech platforms internally (Moderna, etc.). Comparable in life sciences focus and ability to support breakthrough therapeutic platforms, though distinct in its origination-heavy model versus Decheng's external investment approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment128 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Decheng Capital

Life Sciences Venture Capitaldecheng.com

Decheng Capital is a life-sciences-focused venture capital firm founded in 2012 with $2.5B+ AUM, based in Menlo Park with offices in Shanghai and New York, investing across 80+ therapeutic and diagnostic portfolio companies.

What Decheng Capital does

Decheng Capital is a venture capital firm founded in 2012 that invests exclusively in life sciences companies, with assets under management of $2.5 billion or more. The firm is headquartered in Menlo Park, California, with additional offices in Shanghai and New York, providing a tri-continental footprint that supports cross-border deal flow between US and Asia-Pacific biotech ecosystems. Its portfolio spans 80 or more companies across therapeutics, diagnostics, and related life-sciences adjacencies, with the firm maintaining board or board-equivalent roles at more than 50 portfolio companies.

The firm's investment activity is concentrated in private and late-stage private financings, including PIPE transactions, Series A through C rounds, and selective co-leadership of larger syndicates. Recent transactions include a $100M PIPE for Remix Therapeutics (June 2026), a $150M co-led Series B for Syneron Bio (March 2026), and a Series A+ for Vivacta Biotechnology (April 2026). The firm has realized several large exits, notably the sale of portfolio company Alpine Immune Sciences to Vertex Pharmaceuticals for $4.9B in April 2024 and the sale of Prometheus Biosciences to Merck for $10.8B in April 2023, and has supported public-market transitions including the January 2026 IPO of portfolio company Aardvark Therapeutics.

Decheng's revenue model follows the standard venture capital structure of management fees on committed or invested capital plus carried interest on realized gains. The team comprises approximately 13 investment professionals, including recent senior hires Joan Chen (Vice President, July 2025) and Michael Notaras (Vice President, July 2023), suggesting deliberate capacity buildout at the senior investment level. Customer relationships are bilateral: portfolio companies as investees and limited partners as capital providers, with portfolio diversification across 80+ companies reducing single-asset concentration risk.

Decheng Capital firmographics

Firmographics
Name
Decheng Capital
Legal name
Decheng Capital LLC
Website
https://decheng.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Decheng Capital is a life-sciences-focused venture capital firm founded in 2012 with $2.5B+ AUM, based in Menlo Park with offices in Shanghai and New York, investing across 80+ therapeutic and diagnostic portfolio companies.
Ownership category
akta.pro rank

Decheng Capital industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
SIC
Finance Services (6199)
akta.pro industry
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing

Keywords

  • Life sciences venture capital
  • Biotech private equity
  • Healthcare growth equity
  • Venture capital management
  • Biopharma early stage investing

Where Decheng Capital is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Decheng Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Investment Fund Management: As a venture capital/private equity firm managing over $2.5 billion in capital, Decheng generates revenue through management fees charged on assets under management and carried interest/performance fees on successful exits from portfolio companies. Returns are driven by equity ownership stakes in early-stage life science and growth-stage healthcare companies that may exit via IPO (NASDAQ, HKSE, SHA), strategic M&A (e.g., Merck, Vertex, Eli Lilly, Roche, Illumina), or other liquidity events.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Decheng Capital product offering

Product offering

Core offering

Decheng Capital is a venture capital and private equity firm that provides equity capital and active strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with strong market presence. The firm manages over $2.5 billion in assets and invests across biopharma, diagnostics and tools, medical devices, and services, with offices in Silicon Valley, Shanghai, and New York enabling cross-border US-China deal flow. Revenue is generated through management fees on AUM and carried interest/performance fees on successful portfolio exits via IPO, M&A, or other liquidity events.

Product overview

Decheng Capital operates as a single global life sciences investment platform rather than a multi-product suite. Founded in 2012 by Dr. Min Cui, the firm manages over $2.5 billion in assets and provides capital and strategic support to portfolio companies spanning four categories: Biopharma (e.g., Aardvark Therapeutics, CG Oncology, Mammoth Biosciences, Mirvie, Shape Therapeutics, Syneron Bio, Vivacta Biotechnology), Diagnostics and Tools (e.g., Adaptive Biotechnologies, Encodia, LevitasBio, Watchmaker Genomics, AccuraGen), Medical Device (e.g., Nalu Medical, Polares Medical, Centricity Vision, SINO Medical), and Services (e.g., USCI Medical Laboratory). The firm's offering is unified — a life sciences venture capital platform — and is delivered through offices in Silicon Valley (Menlo Park), Shanghai, and New York. Portfolio companies include notable IPOs and exits such as Adaptive Biotechnologies (NASDAQ: ADPT), 3SBio (HKSE: 1530), AK Medical (HKSE: 1789), Invitae (NASDAQ: NVTA), GRAIL (acquired by Illumina), Cue Health (NASDAQ: HLTH), Arcus Biosciences (NASDAQ: RCUS), Terns Pharmaceuticals (NASDAQ: TERN), CG Oncology (NASDAQ: CGON), and others.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early-Stage Life Sciences Venture Capital Investment Equity capital and active strategic support for early-stage life science companies with revolutionary technologies, including board representation and operational involvement. Targets biopharma, diagnostics, medical devices, and tools/services platforms.
  • Growth-Stage Healthcare Growth Equity Investment Growth-stage capital and strategic support to healthcare companies with strong market presence, helping them scale commercialization, expand geographically (especially into China and the US), advance clinical pipelines, and execute cross-border strategies.
  • Cross-Border US-China Life Sciences Investment Platform Integrated investment platform spanning US and China life sciences markets, providing portfolio companies with cross-border strategic support including US clinical development expertise, FDA and NMPA regulatory navigation, China clinical trial site and manufacturing partner access, and global partnership facilitation.

Quantifiable outcome

  • Led a $100 million oversubscribed private placement financing for Remix Therapeutics in connection with its merger with Passage Bio (announced 2026-06-24).
  • +4 more outcomes

Companies that use Decheng Capital

Customer profile

Segments4 records

Ideal customer profiles3 records

Decheng Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Decheng Capital partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Decheng Capital competitors and assessment

Company assessment

Direct peers

  • OrbiMed Advisors: Global healthcare-dedicated investment firm managing ~$17B across private equity, royalty, and public market strategies. Highly comparable to Decheng in life sciences focus and cross-border US-Asia investment activity, with a similar breadth of biopharma, medtech, and diagnostics exposure.
  • Bay City Capital: Life sciences-focused venture capital firm based in San Francisco where multiple Decheng senior team members previously worked (Min Cui, Victor Tong, Dayton Misfeldt, Nick Pliam). Closely comparable investment thesis in biopharma and tools, with similar stage and check-size orientation.
  • Frazier Healthcare Ventures: US-based healthcare-dedicated venture and growth firm investing across biopharma, medical devices, and healthcare services. Comparable in life sciences focus, stage breadth (seed through growth), and portfolio size; Peter Colabuono joined Decheng from Frazier.
  • ARCH Venture Partners: Premier US life sciences venture firm investing across early-stage biotech, genomics, and platform technologies with deep scientific advisor networks. Comparable in modality focus (gene editing, cell therapy, diagnostics) and ability to lead large private financings.
  • Atlas Venture: Boston-based early-stage life sciences venture firm building biotech companies from inception. Comparable in investing across novel modalities (RNA, cell therapy, gene therapy) and stage focus, with comparable check sizes and board-driven model.
  • Qiming Venture Partners: China-based venture firm with significant healthcare and biotech investment activity, frequently co-investing with Decheng (Syneron Bio Series B, others). Comparable in cross-border US-China life sciences investing and biotech platform thesis.
  • Loyal Valley Capital: China-focused investment firm with active healthcare/biotech practice; co-led Vivacta Biotechnology Series A alongside Decheng. Directly comparable as a cross-border life sciences investor with similar modality and stage preferences.
  • 5Y Capital: China-based venture firm investing in technology and healthcare; Joan Chen joined Decheng from 5Y Capital. Comparable in cross-border China-US life sciences investing and stage preferences for early through growth healthcare companies.
  • MPM Capital: US-based biotech-focused investment firm investing across early-stage and public equities in oncology and other life sciences. Comparable in dedicated life sciences focus, ability to lead and co-lead large financings, and portfolio depth.

Broad incumbents

  • Flagship Pioneering: Larger life sciences innovation firm that originates and builds biotech platforms internally (Moderna, etc.). Comparable in life sciences focus and ability to support breakthrough therapeutic platforms, though distinct in its origination-heavy model versus Decheng's external investment approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Decheng Capital social profiles

Digital presence

Decheng Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Decheng Capital leadership team

Management profile

Number of profiles

Profiles13 records

Decheng Capital subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Decheng Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Decheng Capital M&A and investment

M&A and investment

M&A

Investments128 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Decheng Capital

What does Decheng Capital do?

Decheng Capital is a venture capital and private equity firm that provides equity capital and active strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies with strong market presence. The firm manages over $2.5 billion in assets and invests across biopharma, diagnostics and tools, medical devices, and services, with offices in Silicon Valley, Shanghai, and New York enabling cross-border US-China deal flow. Revenue is generated through management fees on AUM and carried interest/performance fees on successful portfolio exits via IPO, M&A, or other liquidity events.

Is Decheng Capital a public or private company?

Decheng Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Decheng Capital founded?

Decheng Capital was founded in 2012. It employs 11 to 50 people.

Where is Decheng Capital based?

Decheng Capital is headquartered in Menlo Park, United States, in the North America region.

How does Decheng Capital make money?

One revenue line is on record: investment Fund Management.

Who are Decheng Capital's main competitors?

Direct peers on record are OrbiMed Advisors, Bay City Capital, Frazier Healthcare Ventures, ARCH Venture Partners, Atlas Venture, Qiming Venture Partners, Loyal Valley Capital, 5Y Capital and MPM Capital. Flagship Pioneering is listed as a broad incumbent.

Does Decheng Capital have an API?

No public API is recorded for Decheng Capital.

What industry is Decheng Capital in?

Decheng Capital's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 523 and its SIC code is 6199.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型Phrontline Closes USD 40 Million Series A for Bispecific and Dual-Payload ADCsPhrontline Biopharma raised nearly $40 million in a Series A led by Oriza Seed and Decheng Capital, following a $60 million Pre-A+ round. The funds will advance clinical development of its bispecific and dual-payload ADCs, including lead asset TJ101, which showed activity in NSCLC and other tumours.ChinaventureSleipnir has completed a Series A financing of over $50 million.SleepTech completed over $50 million in Series A financing led by Decheng Capital, with participation from Huatai Jinrui Fund and China Merchants Venture Capital. The funds will advance clinical development of SP-101 and SP-201, optimize its i-NaS and SynX platforms, and expand its CNS disease pipeline.163Sleptai has completed over $50 million in Series A financing to tackle the research and development of innovative drugs for the central nervous system.Shanghai-based Synphatec completed over $50 million in Series A financing led by Decheng Capital, with participation from Huatai Jinse Fund, China Merchants Venture Capital, and existing shareholders. The funds will support clinical development of SP-101, a rapid antidepressant, and SP-201, an Alzheimer's gene therapy, with Phase Ib/IIa planned within the year.JiemianSleptai completed over $50 million in Series A financing.Sleipnir (Shanghai) Biopharmaceutical Technology Co., Ltd. completed over $50 million in Series A financing on September 28, led by Decheng Capital with follow-on from Huatai Jinse Fund, China Merchants Venture Capital, and existing shareholders. The funds will advance clinical development of SP-101 and SP-201 and optimize the i-NaS and SynX dual technology platforms.36krSleptai has closed a Series A round of over 50 million U.S. dollars.-36氪Sleptai closed a Series A round of over $50 million, led by Decheng Capital with Huatai Kingrui Fund and China Merchants Venture Capital as co-investors. Existing shareholders increased their stakes, and the funds will support clinical development of pipelines SP-101 and SP-201, plus optimization of its i-NaS and SynX platforms.Pedaily宇道生物完成数千万美元C1轮融资,专攻难成药靶标的AI原生BiotechYudao Bio completed a tens-of-millions Series C1 round co-led by Xincheng and Decheng Capital. Its p53 reactivator NTS071 is in Phase I trials, with Phase II planned. The company also plans a NRF2 covalent allosteric molecule Phase I in Q4 2026.Jiemian信宸资本联合领投AI原生Biotech企业宇道生物Xincheng Capital signed a Series C financing agreement with AI-native biotech Yudao Bio on September 15. The round, co-led with Decheng Capital, is tens of millions of dollars, with Dacheng Caizhi, Zhongsheng Xichuang Dingqi Fund, and Dianshi Capital participating, and Dianshi as long-term advisor.Texas CEO MagazineTexas Weekly Deal HighlightsFunction secured $450 million from General Catalyst's Customer Value Fund, a non-equity financing structure that avoids dilution while supporting customer acquisition. Simultaneously, Baylor Genetics closed a $50 million Series B round led by Decheng Capital, valuing the company at $491 million to expand its precision diagnostics capabilities.American City Business JournalsRemix Therapeutics secures $100M, merges with PassageRemix Therapeutics will merge with Passage Bio and go public under the ticker RMTX. The company secured $100 million in private placement financing from Decheng Capital and others. The combined firm has cash to fund operations through 2028.BioSpacePassage Bio and Remix Therapeutics Announce Merger AgreementPassage Bio and Remix Therapeutics announced a definitive all-stock merger, with the combined company operating as Remix Therapeutics. The deal includes a concurrent oversubscribed private placement of approximately $100 million, expected to fund operations into 2028. Passage Bio shareholders will own about 7% of the combined company, with closing expected in Q4 2026.